增强型体外反搏治疗慢性心力衰竭临床疗效的Meta分析  

Clinical efficacy of enhanced external counterpulsation in the treatment of chronic heart failure:a Meta-analysis

作　　者：李吉旭 郭延林[2] 李允强[2] 李伟 梁浩 陆海楠 Li Jixu;Guo Yanlin;Li Yunqiang;Li Wei;Liang Hao;Lu Hainan(Department of Cardiology,the First Clinical Medical College of Nanjing University of Traditional Chinese Medicine,Nanjing 210000,China;Department of Ecephalopathy,Tai'an Hospital of Traditional Chinese Medicine,Tai'an 271000,China;Cardiology Department,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200000,China)

机构地区：[1]南京中医药大学第一临床医学院心内科,南京210000 [2]山东省泰安市中医医院脑病科,泰安271000 [3]上海中医药大学附属龙华医院心内科,上海200000

出　　处：《心脑血管病防治》2024年第2期24-30,共7页CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT

摘　　要：目的运用Meta分析评价增强型体外反搏治疗慢性心力衰竭患者的临床疗效。方法检索中文(中国知网、万方、维普、SinoMed)和英文(Cochrane Library、Embase、Web of Science、PubMed)数据库,收集增强型体外反搏治疗慢性心力衰竭的随机对照试验(RCTs),筛选文献、提取数据后,采用Revman 5.4软件进行Meta分析,对数据采用亚组分析和敏感性分析,发表偏倚采用漏斗图评价。结果共纳入14篇RCTs,共1300例患者;依据不同疗程增强型体外反搏治疗慢性心力衰竭的临床疗效显示,与对照组相比,观察组患者治疗后的6分钟步行距离(6MWD)更远[MD(95%CI)=56.24(44.48~68.00),P<0.01]、N末端B型利钠肽原(NT-proBNP)水平更低[MD(95%CI)=-371.29(-642.63~-99.95),P<0.01]、左心室射血分数(LVEF)水平更高[MD(95%CI)=3.75(2.50~5.01),P<0.01],两组患者不良反应差异无统计学意义[OR(95%CI)=1.62(0.69~3.76),P>0.05]。结论增强型体外反搏治疗慢性心力衰竭患者的临床疗效较好,且安全可靠。Objective To evaluate the clinical efficacy of enhanced external counterpulsation(EECP)in the treatment of patients with chronic heart failure by meta-analysis.Methods Chinese(CNKI,Wanfang,VIP,SinoMed)and English(Cochrane Library,Embase,Web of Science,PubMed)databases were retrieved to collect randomized controlled trials(RCTs)of EECP in the treatment of chronic heart failure.After screening the literatures and extracting the data,meta-analysis was performed using Revman 5.4 software.Sensitivity analysis and subgroup analysis were used to assess the data and funnel plot was used to evaluate publication bias.Results A total of 14 RCTs involving 1300 patients were included.Based on the clinical efficacy of different courses of EECP for chronic heart failure,the results showed that compared to the control group,patients in the observation group had longer 6-minute walk distance(6MWD)[MD(95%CI)=56.24(44.48-68.00),P<0.01],lower N-terminal pro-B-type natriuretic peptide(NT-proBNP)level[MD(95%CI)=-371.29(-642.63--99.95),P<0.01]and higher left ventricular ejection fraction(LVEF)level[MD(95%CI)=3.75(2.50-5.01),P<0.01]after treatment.There was no statistically significant difference in adverse reactions between the two groups[OR(95%CI)=1.62(0.69-3.76),P>0.05].Conclusion EECP therapy has good clinical efficacy,and is safe and reliable for patients with chronic heart failure.

关 键 词：增强型体外反搏 慢性心力衰竭 META分析 有效性 安全性 

分 类 号：R541.6[医药卫生—心血管疾病]